The 2026 guideline introduces AHA/ACC Acute Pulmonary Embolism Clinical Categories to improve severity classification and evidence-based management of acute pulmonary embolism.
Patients with high bleeding risk (HBR) criteria had a 2.99 times higher risk of major adverse cardiovascular events and a 2.28 times higher risk of major bleeding events compared to non-HBR patients.
The Clinical Valve Coordinator is essential for improving access to care and patient outcomes in multidisciplinary teams managing valvular heart disease.
Based on your interests and feeds
Luteolin improved left ventricular ejection fraction (LVEF) and reduced inflammatory factors in atherosclerotic mice, indicating potential as a cardiovascular protective agent.
Anxiety and depression significantly reduced treatment effectiveness and increased major cardiovascular adverse events in ACS patients after PCI, compared to those without these conditions.
DurAVR significantly reduced indexed flow displacement from 4.0%/cm² to 3.5%/cm² and indexed flow reversal ratio from 3.9%/cm² to 2.6%/cm², restoring flow to control values.

“🔴 #EAPCI26 #EHJVSHD Simultaneous Publication 🔴 🫀 Biomimetic TAVR (#DurAVR) restores ascending aortic flow towards native physiology and is associated with 18% LV mass regression at 6 months (first-in-human CMR study) 👉 https://t.co/tV04Wc6RuA @EAPCIPresident https://t.co/LcH1cygHp7”
Patients with phonetically uncommon surnames experienced a 16.8-minute longer FMC-to-diagnosis time compared to those with common surnames (p=0.009).
A multifaceted intervention improved adherence to heart failure guidelines in primary care, achieving 61.8% adherence versus 28.7% in usual care (OR 6.27, p<0.01).
PCI before TAVR did not improve survival or reduce urgent revascularization but decreased nonurgent revascularization, with increased bleeding risk (OR 1.59).
Discordant low-gradient aortic stenosis exhibited a steeper median PCWP/CO-slope of 3.3 mm Hg/L/min compared to 1.9 mm Hg/L/min in moderate AS, indicating severe AS physiology.